Sixty experts from public health agencies, pharmaceutical companies, nongovernmental organizations, and philanthropic foundations met in London for a two-day conference to discuss ways to make HPV vaccines available to women in developing countries.In clinical trials, GlaxoSmithKline's experimental HPV vaccine Cervarix have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70 percent of cervical cancer cases. According to the World Health Organization 500,000 women worldwide are diagnosed with cervical cancer annually, 80 percent of whom live in developing countries. (Medical News)
